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Karlsson, Sven, Anton J. W. Scheurink, and Bo
Ahre´n. Gender difference in the glucagon response to gluco-
penic stress in mice. Am J Physiol Regulatory Integrative
Comp Physiol 282: R281–R288, 2002.—A gender difference
in the glucagon response to insulin-induced hypoglycemia
was previously demonstrated in humans. Whether this re-
flects a gender difference in autonomic activation or in pan-
creatic a-cell regulation is not known. We investigated the
glucagon, epinephrine, and norepinephrine responses to neu-
roglycopenic stress induced by 2-deoxy-D-glucose (2-DG) or
insulin in female and male mice. 2-DG increased plasma
glucagon levels by 5596 68% in females versus 2816 46% in
males (P , 0.01). Plasma levels of epinephrine or norepi-
nephrine after 2-DG administration did not differ between
genders. During insulin-induced hypoglycemia, the glucagon
response was similarly higher in females (P , 0.001),
whereas the plasma catecholamine response was higher in
males (P , 0.05). In vivo, the glucagon response to carbachol
or clonidine was higher in females (P , 0.05). In isolated
islets, the glucagon response to carbachol (100 mM; P 5
0.003) but not to clonidine (1 mM) was larger in females. We
conclude that in addition to a larger a-cell mass (previously
described in female mice), an increased sensitivity of the
glucagon-producing a-cell to cholinergic activation contrib-
utes to the larger glucagon response to glucopenic stress in
female mice.
hypoglycemia; autonomic nervous system; epinephrine; nor-
epinephrine; males; females
THE EARLY COUNTERREGULATORY RESPONSE to insulin-in-
duced hypoglycemia involves autonomic activation and
increased glucagon secretion to restore plasma glucose
levels (4, 8, 13, 15, 31). Several studies on the counter-
regulatory glucagon and catecholamine responses to
insulin-induced hypoglycemia reported an intriguing
gender difference in healthy human subjects as well as
in diabetic subjects (3, 9, 11). Thus although all of these
studies revealed that the epinephrine response to in-
sulin-induced hypoglycemia was lower in females than
in males, a diminished glucagon response in females
was reported in some (9, 11) but not all (3) studies.
It is not known whether the gender difference in the
autonomic response to insulin-induced hypoglycemia
underlies the difference in glucagon secretion. In addi-
tion, although many studies regarding glucopenic
stress have been performed in rodents and other spe-
cies (for a review, see Ref. 15), data regarding gender
differences in the counterregulatory response to gluco-
penic stress are scarce for species other than humans.
The aim of the present study was first to explore
whether a gender difference in the autonomic and
glucagon-secretion responses to glucopenic stress does
exist in mice, and if so, whether these differences are
caused by changes in autonomic activation or by
changes in a-cell activity. Both insulin-induced hypogly-
cemia and the glucose analog 2-deoxy-D-glucose (2-DG)
were used in this study as models for glucopenic stress.
The glucose analog 2-DG activates the autonomic
nervous system through central neuroglycopenia (7,
15, 24, 32) and allows us to dissociate the effects of
hypoglycemia from those of insulin. Thus interpreta-
tion of results using insulin-induced hypoglycemia to
induce glucopenic stress is hampered by findings that
high concentrations of insulin per se may exaggerate
the sympathetic autonomic response to insulin-in-
duced hypoglycemia in normal human subjects (9, 10).
Moreover, exogenous insulin itself may inhibit gluca-
gon secretion as well as endogenous insulin secretion
(27, 31).
In the present study, the following two experiments
were performed on mice: 1) comparison of the early
glucagon and plasma catecholamine responses to 2-DG-
induced neuroglycopenia or insulin-induced hypoglyce-
mia in female and male mice, and 2) comparison of the
glucagon-producing a-cell response to direct cholin-
ergic or adrenergic activation between genders both in
vivo and in vitro in isolated islets of Langerhans.
MATERIALS AND METHODS
Animals. Nonfasted, unanesthetized male (body wt 35–45
g) and female (body wt 25–35 g) mice (age 12–14 wk) of the
NMRI strain (Bolmholdtgaard Breeding and Research Cen-
ter, Ry, Denmark) were used throughout the study. The
animals were fed a standard pellet diet and tap water ad
libitum. Experiments were performed between 1 and 3 PM.
The time of the estrous cycle of the female mice was not
considered. The study was approved by the Ethics Committee
for Animal Research of Lund University.
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Studies in vivo. We injected 2-DG (Sigma Chemical, St.
Louis, MO) at a dose of 0.3, 1.5, or 3 mmol/kg iv into a tail
vein (volume load 10 ml/kg body wt). Control animals were
injected with 0.9% NaCl. Blood was sampled from the retro-
bulbar plexus after 2 or 10 min for the determination of
glucose, insulin, and glucagon values. In separate experi-
ments, blood was sampled at 2 or 10 min after injection of
2-DG (3 mmol/kg iv) for determination of plasma levels of
epinephrine and norepinephrine. For these time points, the
insulin and glucagon responses to 2-DG (3 mmol/kg) have
previously been shown to be markedly increased in female
mice (16, 18). Insulin-induced hypoglycemia in mice was
performed by injection of insulin (2 U/kg body wt ip; Actrapid,
Novo Nordisk, Bagsvaerd, Denmark) as previously described
(14). Controls were injected with 0.9% NaCl. Blood was
sampled 15 min after the intraperitoneal injection. Plasma
was separated by centrifugation, and samples were stored at
220°C until analysis for insulin, glucagon, and glucose con-
tents. Blood samples (250 ml) for catecholamine determina-
tion were immediately transferred into chilled tubes contain-
ing 10 ml of heparin (500 IU/ml; Lo¨vens Chemical Industries,
Ballerup, Denmark) and EDTA (10 mg/ml heparin; Merck,
Darmstadt, Germany) and centrifuged, and plasma was
stored at 270°C until assay for catecholamine content. To
study the acute glucagon response to cholinergic or adrener-
gic stimulation, male and female mice were injected (volume
load 10 ml/kg body wt) with the muscarinic agonist carbachol
(0.16 mmol/kg iv) or the a2-adrenergic agonist clonidine (50
nmol/kg iv), and blood was sampled after 2 min. At these
dosage levels, carbachol or clonidine, respectively, have pre-
viously been shown to induce a peak increase in the plasma
glucagon levels 2 min after injection in female mice (2, 29).
Isolation and incubation of islets. Islets from male and
female mice were isolated by the collagenase-digestion tech-
nique as initially described by Lacy and Kostianovsky (19)
with slight modifications. In short, during pentobarbital so-
dium (120 mg/kg) anesthesia, a catheter was inserted
through the common bile duct and the duodenal papilla was
occluded. Thereafter the pancreas was retrogradely filled
with 3 ml of Hanks’ balanced salt solution (Sigma) supple-
mented with 0.3 mg/ml of collagenase (Collagenase P, Boeh-
ringer Mannheim, Germany). The pancreas was removed
and incubated at 37°C for 20–22 min. Islets were thereafter
hand-picked under a stereomicroscope and cultured over-
night in RPMI-1640 medium (GIBCO, Paisley, UK) supple-
mented with 10% fetal calf serum (Biological Industries,
Kibbutz Beit Haemek, Israel), 2.06 mmol/l L-glutamine, 100
IU/ml penicillin, 100 mg/ml streptomycin (Biological Indus-
tries), and 2.5 mg/ml amphotericin B (GIBCO). After the
overnight culture period, the islets were preincubated for 60
min in HEPES buffer supplemented by 0.1% human serum
albumin and 3.3 mM glucose. The buffer contained (in mM)
25 HEPES, 125 NaCl, 5.9 KCl, 1.28 CaCl2, and 1.1 MgCl2.
The pH (7.36) of the HEPES buffer was adjusted with NaOH.
Batches of three islets were thereafter incubated in a 200-ml
volume of HEPES buffer supplemented with human serum
albumin, 1.8 mM glucose, and 5 mM L-arginine (Sigma) for
60 min at 37°C in an atmosphere of humidified air saturated
with 5% CO2. During the experiments, 0.1 mM carbachol
(Sigma), 1 mM clonidine (Sigma), or 10 mM L-arginine was
added according to the protocols. After the incubation period,
medium was removed and analyzed by radioimmunoassay
for insulin (25 ml) and glucagon (100 ml) contents. Aprotinin
(Trasylol; Bayer, Leverkusen, Germany) at a final concentra-
tion of 1,000 kIU/ml was added to the test tubes for glucagon
analysis.
Determinations of insulin, glucagon, glucose, and cate-
cholamines. Insulin was determined by radioimmunoassay
using a guinea pig anti-rat insulin antibody (125I-labeled
human insulin) as a tracer and rat insulin as a standard
(Linco Research, St. Charles, MI). The separation of free and
bound radioactivity was performed via the double-antibody
technique using a goat anti-guinea pig IgG antibody (Linco).
Plasma glucagon levels were determined by radioimmunoas-
say using the glucagon antibody 125I-glucagon and a gluca-
gon standard from Linco. Plasma glucose levels were deter-
mined with the glucose oxidase method. Epinephrine and
norepinephrine were analyzed from plasma by liquid chro-
matography in combination with electrochemical detection
as previously described (26, 28).
Statistics. Data are presented as means 6 SE. One-way
ANOVA preceded the Bonferroni test or the Student-New-
man-Keuls test for correction of multiple comparisons or
Student’s t-test for unpaired observations was used for sta-
tistical evaluation. A value of P , 0.05 was considered sig-
nificant. When comparisons were made between males and
females with respect to any differences in magnitude of the
response to a certain agonist, the differences in plasma levels
of insulin or glucagon compared with NaCl-injected controls
were also calculated and expressed in either absolute figures
or in percentages (controls set to 100%). For evaluation of any
differences between females and males in plasma levels of
insulin, glucagon, and glucose during control conditions, all
NaCl-injected control animals from which blood was sampled
after 2 min were included for statistical comparison.
RESULTS
Baseline plasma glucagon, insulin, and glucose lev-
els. Values of plasma insulin, glucagon, and glucose
levels obtained from all NaCl-injected animals where
blood was sampled after 2 min are summarized in
Table 1. Males exhibited higher plasma insulin and
lower plasma glucagon levels compared with females
under these conditions.
Glucagon and insulin response to 2-DG-induced neu-
roglycopenia. At 10 min after injection of 2-DG (1.5 or
3.0 mmol/kg iv), plasma levels of glucagon, insulin, and
glucose markedly increased in both male and female
mice (Fig. 1). In contrast, at 0.3 mmol/kg of 2-DG, no
effect on these parameters was observed (n 5 16; not
significant; data not shown). The glucagon response to
2-DG (1.5 or 3.0 mmol/kg) was, however, markedly
higher in females compared with males (P , 0.001; Fig.
1A). Thus at the 1.5 mmol/kg dose of 2-DG, plasma
glucagon levels increased by 559 6 68% in females but
only 281 6 46% in males (P , 0.01; n 5 10/group). Also
Table 1. Basal plasma levels of insulin, glucagon,
and glucose in male and female mice
Male Female P Value
P-insulin, pmol/l 420643 238627 0.001
P-glucagon, pg/ml 98611 195629 0.003
P-glucose, mmol/l 9.360.3 960.2 0.377
Values are means 6 SE. Plasma levels of insulin (P-insulin),
glucagon (P-glucagon), and glucose (P-glucose) levels in nonfasted
female (n 5 36) and male (n 5 34) mice at 2 min after intravenous
injection of NaCl. Animals were used as controls in experiments
presented in Figs. 3 and 4.
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at the earlier time point of 2 min, plasma glucagon
levels were markedly higher in females compared with
males in response to 2-DG (Table 2). In contrast,
plasma levels of insulin after 2-DG were increased to
the same extent in both genders (Fig. 1C). The glucose
response was the same for the two doses of 2-DG;
however, a higher plasma insulin level was obtained
after injection of 3.0 mmol/kg compared with 1.5
mmol/kg of 2-DG in both females (P 5 0.01) and males
(P 5 0.004). Plasma glucose levels after NaCl injection
were slightly higher in males compared with females
(10.2 6 0.4 vs. 8.7 6 0.5 mmol/l; P 5 0.011) but did not
differ between genders after injection of 2-DG at a dose
of 1.5 mmol/kg (P 5 0.378) or 3.0 mmol/kg (P 5 0.157).
Furthermore, NaCl-injected male controls exhibited
higher plasma levels of insulin (369 6 69 vs. 166 6 18
pmol/l; P 5 0.011) and lower plasma levels of glucagon
(74 6 10 vs. 126 6 13 pg/ml; P 5 0.004) compared with
NaCl-injected female controls. These results show that
the glucagon but not the insulin or glucose responses to
2-DG-induced neuroglycopenia are markedly higher in
female compared with male mice.
Sympathoadrenal activation by 2-DG. To investigate
whether the gender difference in the glucagon response
to 2-DG is caused by gender differences in the activa-
tion of the sympathetic branch of the autonomic ner-
vous system, plasma epinephrine and norepinephrine
were measured 10 min after 2-DG-injection in female
and male mice. It was found that 2-DG (3.0 mmol/kg)
administration leads to a significant increase in plasma
epinephrine levels (P , 0.001 for both females and
males) but not norepinephrine levels (Fig. 2). There
was no gender difference in the epinephrine response.
The only significant gender difference observed was in
norepinephrine levels after NaCl injection that were
slightly higher in males than in females (5.7 6 0.7 vs.
3.3 6 0.4 ng/ml; P 5 0.028). Also at the earlier time
point of 2 min, there were no differences in the epi-
nephrine or norepinephrine levels after 2-DG adminis-
tration between genders, although plasma norepineph-
rine levels were slightly higher after NaCl injection in
males compared with females (P , 0.05; Table 2). At
this time point, 2-DG did not induce any significant
change in either epinephrine or norepinephrine levels
(Table 2). These results show that the degree of sym-
pathoadrenal activation after 2-DG-induced neurogly-
copenia, as reflected by plasma catecholamine levels, is
similar in male and female mice.
Acute glucagon response to cholinergic or adrenergic
activation. We next aimed to investigate whether the
gender difference in glucagon response to 2-DG-in-
duced neuroglycopenia may be attributed to a differ-
ence in the sensitivity of the islet glucagon-producing
cells to cholinergic or a2-adrenergic stimulation. Mice
were injected with the muscarinic agonist carbachol or
Fig. 1. Plasma levels of glucagon (A), glucose (B), and insulin (C) 10
min after an injection of 2-deoxy-D-glucose (2-DG) at concentrations
of 1.5 or 3.0 mmol/kg iv in female and male mice. Controls were
injected with 0.9% NaCl. Means 6 SE of 10 animals in each group
are shown; *P , 0.05 between males and females.
Table 2. Plasma levels of glucagon, epinephrine, and norepinephrine at 2 min after 2-deoxy-D-glucose injection
Female Male
NaCl, 0.9% 2-DG (3 mmol/kg) NaCl, 0.9% 2-DG (3 mmol/kg)
Glucagon, pg/ml 111614 836651 10566 242623*
Epinephrine, ng/ml 6.360.7 8.360.4 7.260.7 8.660.6
Norepinephrine, ng/ml 7.260.8 660.5 10.460.9* 8.261
Values are means 6 SE of measurements on plasma from 10 mice in each group. Experiments were performed on two different occasions
with 5 mice in each group. *P , 0.05, significant difference between males and females. 2-DG, 2-deoxy-D-glucose.
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the a2-adrenergic agonist clonidine. These drugs stim-
ulate glucagon secretion through direct action on the
a-cells. Carbachol (0.16 mmol/kg) increased plasma
glucagon levels by 402 6 79 pg/ml in females and 90 6
13 pg/ml in males (Fig. 3A; P 5 0.001 males vs. fe-
males), which corresponds to a 140 6 30% increase in
females and a 71 6 16% increase in males (P 5 0.044).
Plasma insulin levels after carbachol injection did not
differ between genders (P 5 0.572). However, because
plasma levels of insulin were higher in males during
control conditions, the calculated increase in insulin
after carbachol injection was lower in males (increase
of 637 6 116 in males vs. 1,174 6 226 pmol/l in females;
P 5 0.042). Plasma glucose levels were slightly higher
in carbachol-injected males compared with females
(11.1 6 0.4 vs. 9.9 6 0.2 mmol/l; P 5 0.014). The
adrenergic agonist clonidine (50 nmol/kg) increased
plasma glucagon levels from 81 6 6 to 232 6 16 pg/ml
in females (P , 0.001) and from 54 6 8 to 97 6 10 pg/ml
in males (P 5 0.054; Fig. 4A). Thus clonidine increased
plasma glucagon levels by 189 6 20% in females and
79 6 19% in males (P , 0.001, male vs. female).
Plasma glucose levels were slightly elevated by
clonidine in males (P 5 0.003) but were not affected in
females. Plasma insulin levels did not differ between
groups. In summary, these results show that the acute
glucagon response to cholinergic or adrenergic activa-
tion is markedly higher in female mice compared with
males.
Glucagon secretion from isolated islets. To directly
study any differences in the sensitivity of the glucagon-
producing a-cells to autonomic activation, isolated is-
lets were used. The basal medium contained 1.8 mM
glucose and 5 mM L-arginine to optimize the conditions
for stimulation of glucagon secretion. The muscarinic
receptor agonist carbachol (100 mM) stimulated gluca-
gon secretion to a greater extent in islets from female
mice compared with those from males (10.6 6 1.1
pgzislet21z60 min21 in females vs. 5.8 6 0.9 pgzislet21z60
min21 in males; P 5 0.003; n 5 16 in each group; Fig.
5A). Glucagon secretion was increased by 10 mM
L-arginine or clonidine (5 mM) to a similar extent in
islets from both genders (Fig. 5A). Insulin secretion
Fig. 3. Plasma levels of glucagon (A), glucose (B), and insulin (C) 2
min after injection of the muscarinic agonist carbachol (0.16 mmol/kg
iv). Controls were injected with NaCl. Means 6 SE of 20 animals in
each group are shown; *P , 0.05 between males and females.
Fig. 2. Plasma levels of epinephrine (A) and norepinephrine (B) in
female and male mice 10 min after an injection of 2-DG (3.0 mmol/kg
iv). Controls were injected with NaCl. Means 6 SE of 10 animals in
each group are shown; *P , 0.05 between males and females.
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monitored from the same experiments revealed an
increased insulin secretory response to carbachol in
islets from females compared with those from males
(P , 0.001; Fig. 5B). These experiments therefore re-
veal an increased sensitivity of the glucagon-producing
a-cells of female mice to cholinergic stimulation.
Insulin-induced hypoglycemia. Because our results
of an increased glucagon response to 2-DG-induced
glucopenic stress in female mice is in contrast to pre-
vious studies in humans using insulin-induced hypo-
glycemia to induce glucopenic stress, insulin-induced
hypoglycemia was also investigated in mice. At 15 min
after injection of insulin (2 U/kg ip), plasma glucose
levels were 3.5 6 0.1 mmol/l in females and 3.8 6 0.1
mmol/l in males (not significant; Fig. 6). In NaCl-
injected controls, plasma glucagon levels were 188 6
29 pg/ml in females and 64 6 5 pg/ml in males (P ,
0.001). Plasma glucagon levels were elevated to
1,069 6 88 in females and 307 6 39 in males (P ,
0.001). Thus after insulin-induced hypoglycemia, plasma
glucagon levels are considerably higher in female com-
pared with male mice.
Sympathoadrenal activation by insulin-induced hy-
poglycemia. In a separate series of experiments, the
plasma epinephrine and norepinephrine responses to
insulin-induced hypoglycemia were explored. It was
found that both plasma epinephrine and norepineph-
rine levels were higher in males compared with fe-
males 15 min after insulin injection (P , 0.05; Table 3).
There were no differences in the degree of glycemia
between genders (4.2 6 0.4 mmol/l in females vs. 4.4 6
0.4 mmol/l in males; not significant). Also in this series
of experiments, the glucagon response to insulin-in-
duced hypoglycemia was considerably higher in fe-
males compared with males (P , 0.001; Table 3). Thus
despite the lower plasma catecholamine response, a
higher plasma glucagon response is observed in fe-
males after insulin-induced hypoglycemia, which sug-
Fig. 5. Glucagon (A) and insulin (B) secretion from isolated islets of
Langerhans incubated for 60 min in a HEPES buffer containing 1.8
mM glucose with the addition of either 5 or 10 mM L-arginine (Arg 5
and Arg 10, respectively), 5 mM L-arginine 1 100 mM carbachol (Arg
5 1 Carb), or 5 mM L-arginine 1 1 mM clonidine (Arg 5 1 Clon).
Means 6 SE of 14–16 batches of 3 islets/batch are shown; *P , 0.05,
islets from males vs. females.
Fig. 4. Plasma levels of glucagon (A), glucose (B), and insulin (C) 2
min after an injection of the a2-adrenergic agonist clonidine (50
nmol/kg iv). Controls were injected with NaCl. Means 6 SE of 15–16
animals in each group are shown; *P , 0.05 between males and
females.
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gests that the mechanism underlying the higher glu-
cagon response to glucopenic stress in female mice does
not rely on differences in the degree of sympathoadre-
nal activation.
DISCUSSION
The main finding from the present study is that
female mice have a larger glucagon response to 2-DG
and insulin-induced hypoglycemia than their male
counterparts, and that this increased response may be
attributed to increased sensitivity of the glucagon-
producing a-cells to cholinergic activation rather than
to increased sympathoadrenal activation.
It has been shown that 2-DG induces autonomic
nervous activation and increases glucagon secretion in
several species including humans (15). It has also been
demonstrated that in female mice, both the 2-DG- and
hypoglycemia-induced increases in glucagon secretion
are caused by simultaneous activation of the cholin-
ergic and adrenergic branches of the autonomic ner-
vous system (14, 16–18). Hence ganglionic, muscarinic,
as well as a-adrenergic blockade inhibit the glucagon
response. In the present study, we demonstrated a
markedly higher glucagon response to 2-DG or insulin-
induced hypoglycemia in female compared with male
mice. This difference could not be attributed to gender
differences in the degree of sympathoadrenal activa-
tion, because the plasma epinephrine or norepineph-
rine levels did not differ between males and females
after 2-DG-injection, and those levels were higher in
males compared with females during insulin-induced
hypoglycemia. Instead, our study suggests that the
difference between genders in the glucagon response
relies on a higher glucagon secretory response to the
given degree of autonomic activation in females, be-
cause both carbachol- and clonidine-induced glucagon
secretion were enhanced in females compared with
males. It has previously been shown that the glucagon
pancreatic content is increased in female compared
with male mice (5, 6). The possibility therefore exists
that an increased a-cell mass might contribute to the
larger glucagon response observed in females. The ex-
periments in isolated islets, however, revealed that the
glucagon response to cholinergic but not adrenergic
activation was enhanced in islets from females com-
pared with males. This implies that in addition to an
increased a-cell mass in females, an increased sensi-
tivity of the glucagon-producing a-cell to cholinergic
activation exists in females. Theoretically, a gender
difference in the degree of parasympathetic activation
by glucopenic stress might also underlie the gender
difference in the glucagon response. Such a difference
cannot be excluded by the present study, but even if
Fig. 6. Plasma levels of glucagon (A), glucose (B), and insulin (C) at
15 min after injection of insulin (2 U/kg body wt ip) or NaCl. Means 6
SE of 18–20 animals/group are shown; *P , 0.05 between males and
females.
Table 3. Plasma levels of glucagon, epinephrine, and norepinephrine during insulin-induced hypoglycemia
Female Male
NaCl, 0.9% Insulin (2 U/kg) NaCl, 0.9% Insulin (2 U/kg)
Glucagon, pg/ml 110615 495666 8766 196623*
Epinephrine, ng/ml 6.161.2 8.460.4 7.160.8 11.261.1*
Norepinephrine, ng/ml 6.260.9 6.760.5 9.261.2 13.161.7*
Values are means 6 SE. Plasma levels of glucagon, epinephrine, and norepinephrine 15 min after intraperitoneal injection of insulin.
Values are measurements of plasma (n 5 10 mice/group). Experiments were performed on two different occasions (n 5 5 mice/group). *P ,
0.05, significant difference between males and females.
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such a difference exists, our study demonstrates that
an increased sensitivity to cholinergic activation might
contribute to the gender difference in the glucagon
response to glucopenic stress in mice. This increased
sensitivity could theoretically be attributed to gender
differences in the number or the functioning of cholin-
ergic receptors on the pancreatic a-cells under the
influence of, for example, sex hormones. Whether any
such influences exist with respect to the a-cell is not
known. On the contrary, it has been shown previously
(12) that testosterone or progesterone (in contrast to
corticosteroids) does not affect a2-adrenoceptor density
in insulin-producing HIT-T15 cells.
An intriguing observation of the present study was
that the glucagon response to the a2-adrenoceptor ag-
onist clonidine was higher in females under in vivo
conditions but not in isolated islets. This points to a
gender difference in the sensitivity to the central ac-
tion, i.e., an indirect, extra-islet action of clonidine.
Clonidine is known to decrease central sympathetic
outflow by inhibiting hypothalamic norepinephrine re-
lease by presynaptic action in combination with hyper-
glycemia induced by a central postsynaptic mechanism
(22, 30). Two possible mechanisms might therefore
explain our results: 1) clonidine induces a more pro-
nounced decrease in sympathetic outflow from the cen-
tral nervous system in males compared with females
concomitantly with an equal effect on the postsynaptic
receptors on the glucagon cells; and 2) the increase in
plasma glucose levels induced by clonidine, which was
observed in males only, restrains the glucagon re-
sponse. Thus a slight hyperglycemia in combination
with the lower glucagon response in males but not in
females was also observed after carbachol administra-
tion. It is, however, unlikely that the small increase in
glycemia induced by either of the autonomic agonists
would significantly contribute to the observed gender
difference in the glucagon responses, because glucagon
secretion usually does not change in the range of glu-
cose concentration between 5 and 11 mM (25). The
gender difference in the glucagon response to clonidine
is therefore most likely centrally governed.
Previously, insulin was shown to suppress the glu-
cagon response during insulin-induced hypoglycemia
in both normal human subjects and type 1 diabetics
(20, 21). However, such an action does not explain the
observed gender difference in the glucagon response to
2-DG or insulin-induced hypoglycemia in this study,
because plasma insulin levels increased to an equal
extent in both genders. On the contrary, the insulin
response to cholinergic agonism was lower in males,
which would tend to increase (not reduce) glucagon
secretion.
Our finding of a higher glucagon response to 2-DG
and insulin-induced hypoglycemia in female mice is in
contrast to studies in humans during insulin-induced
hypoglycemia; in two studies, a decreased glucagon
response was found in females, whereas no difference
between genders was evident in one study (3, 9, 11).
The mechanism underlying this difference between
humans and mice is not known, but our results empha-
size a fundamental species difference regarding the
regulation of the glucagon response to glucopenic
stress between humans and mice. Regarding the sym-
pathoadrenal component of the counterregulatory re-
sponse to glucopenia, we found plasma catecholamines
to be higher in males during insulin-induced hypogly-
cemia, which is in agreement with previous studies in
human subjects where a higher epinephrine response
was observed in males during insulin-induced hypogly-
cemia (3, 9, 11). In contrast, during 2-DG-induced
glucopenic stress, no gender differences in the plasma
levels of epinephrine and norepinephrine were ob-
served in the present study in mice, which indicates a
gender-dependent difference in the counterregulatory
response between glucopenic stress induced by insulin
and that induced by 2-DG.
Although the present study was not designed to
investigate any differences in basal plasma levels of
insulin, glucagon, and glucose, we found in the 2-DG
experiments that nonfasting plasma glucose levels
were slightly higher in control males compared with
control females. However, this was not the case when
all 2-min control plasma glucose values were com-
pared. This might be interpreted as if males have a
tendency toward higher plasma glucose levels com-
pared with females, and that a slight stress-related
hyperglycemia occurs at 10 min compared with 2 min.
This hypothesis is supported by the finding of higher
plasma norepinephrine levels in males compared with
females during control conditions. Previously, in stud-
ies on humans, females have been shown to have a
lower capacity to maintain glycemia during fasting
compared with males (9, 23), and in mice of the NMRI
strain, fasting plasma glucose levels are lower in fe-
males compared with males (1). During control condi-
tions, males exhibited higher plasma insulin concen-
trations, which indicates decreased insulin sensitivity
in males compared with females. This confirms previ-
ous observations in the NMRI mouse (1, 5, 6). It might
be speculated that the higher plasma insulin levels
contribute to the lower plasma glucagon levels that are
also observed in males, because insulin is known to
inhibit glucagon secretion by a paracrine or endocrine
mechanism within the islets (27). To what extent differ-
ences in sex hormones or other gender-dependent mech-
anisms contribute to the differences in the parameters of
glucose homeostasis observed between genders in the
present study remains to be established. However, our
study emphasizes the existence of a gender-dependent
regulation of carbohydrate metabolism in mice.
From the present study, we conclude that in the
NMRI mouse, 1) the glucagon response to glucopenic
stress induced by 2-DG or insulin-induced hypoglyce-
mia is markedly larger in female compared with male
mice; 2) the mechanism underlying the increased glu-
cagon response does not rely on a different degree of
sympathoadrenal activation; and 3) the pancreatic
a-cell of females has an increased sensitivity to cholin-
ergic activation, which may contribute to the larger
glucagon response observed in females during gluco-
penic stress.
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The present study has clearly demonstrated that
gender is an important determinant for the regulation
of glucose homeostasis in mice, which was previously
demonstrated for other species including humans. The
present study, however, emphasizes that the influence
of gender might differ between species. Thus the ob-
servation that the glucagon response to glucopenia is
larger in female mice than in male mice contrasts to
the results of previously published studies in humans,
which report that glucagon responses to insulin-in-
duced hypoglycemia are larger in men than in women.
The present study demonstrates that an increased
sensitivity of the a-cell to cholinergic activation might
contribute to the larger glucagon response to gluco-
penic stress in mice. Because the pancreatic content of
glucagon has previously been demonstrated to be in-
creased in female versus male mice, the possibility
exists that an increased a-cell mass also contributes to
the enhanced glucagon response in females. The exact
mechanisms underlying the gender differences in glu-
cose homeostasis have not been established. Future
studies, particularly those examining the influence of
reproductive hormones, are warranted.
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